A comprehensive evidence package to support reimbursement decisions in RA
Our client was launching a new product into the crowded rheumatoid arthritis (RA) market. They needed support to:
- synthesise a comprehensive package of evidence suitable for global reimbursement decisions for the use of an alternative treatment in moderate to severe RA
- provide a robust evidence base for the communication of the burden of moderate to severe RA and the value of an alternative therapy with a novel mode of action
We implemented a series of systematic reviews to identify RA clinical trial data covering efficacy and safety, published cost-effectiveness (CE) models, and humanistic and economic burden.
We evaluated the comparative efficacy and safety of our client’s novel product compared with currently licensed treatments using indirect treatment comparison methods.
Network meta-analysis outputs informed a CE model and key value messaging.
Our health economics team developed the CE model and a budget impact model in order to demonstrate value across global markets.
A drug acquisition model for the US was also developed to support key account managers in sub-national negotiations.
The evidence package informed successful European reimbursement decisions, including the National Institute for Health and Clinical Excellence (NICE).
Our client’s product is placed in an advantageous position within a competitive treatment environment across Europe.